These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1227 related articles for article (PubMed ID: 20717121)

  • 1. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.
    Vollenweider FX; Kometer M
    Nat Rev Neurosci; 2010 Sep; 11(9):642-51. PubMed ID: 20717121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
    De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
    Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelics in the treatment of unipolar mood disorders: a systematic review.
    Rucker JJ; Jelen LA; Flynn S; Frowde KD; Young AH
    J Psychopharmacol; 2016 Dec; 30(12):1220-1229. PubMed ID: 27856684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychedelic Drugs in Biomedicine.
    Kyzar EJ; Nichols CD; Gainetdinov RR; Nichols DE; Kalueff AV
    Trends Pharmacol Sci; 2017 Nov; 38(11):992-1005. PubMed ID: 28947075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.
    Mertens LJ; Preller KH
    Pharmacopsychiatry; 2021 Jul; 54(4):176-190. PubMed ID: 33472250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelic drugs for psychiatric disorders.
    da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
    J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications.
    Kraehenmann R
    Curr Neuropharmacol; 2017; 15(7):1032-1042. PubMed ID: 28625125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psilocybin and Other Classic Psychedelics in Depression.
    Nutt DJ; Peill JM; Weiss B; Godfrey K; Carhart-Harris RL; Erritzoe D
    Curr Top Behav Neurosci; 2024; 66():149-174. PubMed ID: 37955822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychedelics: Where we are now, why we got here, what we must do.
    Belouin SJ; Henningfield JE
    Neuropharmacology; 2018 Nov; 142():7-19. PubMed ID: 29476779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychedelic medicines for mood disorders: current evidence and clinical considerations.
    Sarris J; Pinzon Rubiano D; Day K; Galvão-Coelho NL; Perkins D
    Curr Opin Psychiatry; 2022 Jan; 35(1):22-29. PubMed ID: 34855694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychedelics and music: neuroscience and therapeutic implications.
    Barrett FS; Preller KH; Kaelen M
    Int Rev Psychiatry; 2018 Aug; 30(4):350-362. PubMed ID: 30240282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The renaissance in psychedelic research: What do preclinical models have to offer.
    Murnane KS
    Prog Brain Res; 2018; 242():25-67. PubMed ID: 30471682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Out of the box: A psychedelic model to study the creative mind.
    Kuypers KPC
    Med Hypotheses; 2018 Jun; 115():13-16. PubMed ID: 29685188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Applications of Classic Hallucinogens.
    Bogenschutz MP; Ross S
    Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular insights into psychedelic drug action.
    Slocum ST; DiBerto JF; Roth BL
    J Neurochem; 2022 Jul; 162(1):24-38. PubMed ID: 34797943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents.
    McIntyre RS
    Expert Opin Drug Saf; 2023; 22(10):885-889. PubMed ID: 37635320
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 62.